Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $30.62.

A number of research firms have recently commented on TVTX. HC Wainwright lifted their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Evercore ISI boosted their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Citigroup boosted their price target on Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. lifted their price objective on Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th.

Insider Transactions at Travere Therapeutics

In other news, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at $945,842.94. The trade was a 21.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the completion of the transaction, the insider now directly owns 59,883 shares in the company, valued at $1,143,765.30. The trade was a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 206,335 shares of company stock valued at $4,453,012 in the last three months. 3.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Travere Therapeutics in the 4th quarter worth approximately $31,000. Sterling Capital Management LLC raised its position in Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock worth $41,000 after purchasing an additional 2,115 shares during the last quarter. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter worth approximately $53,000. Gen Wealth Partners Inc bought a new position in Travere Therapeutics in the 4th quarter worth approximately $73,000. Finally, Quarry LP bought a new position in Travere Therapeutics in the 3rd quarter worth approximately $105,000.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $19.73 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock’s 50-day moving average is $20.33 and its two-hundred day moving average is $17.71. The firm has a market cap of $1.75 billion, a P/E ratio of -4.81 and a beta of 0.75. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. On average, analysts anticipate that Travere Therapeutics will post -1.4 earnings per share for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.